Lipocine Ownership | Who Owns Lipocine?

Overview Forecast RevenueFinancials Chart

Lipocine Ownership Summary

Lipocine is owned by 11.94% institutional investors, 4.63% insiders, and 83.43% retail investors. Ikarian capital is the largest institutional shareholder, holding 9.33% of LPCN shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.64% of its assets in Lipocine shares.

LPCN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Lipocine	11.94%	4.63%	83.43%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ikarian capital	508.56K	9.33%	$4.06M
Eversept partners, lp	294.99K	5.41%	$2.36M
Vanguard group	221.87K	4.10%	$1.78M
Rosalind advisors	221.62K	4.07%	$1.77M
Aigh capital management	200.00K	3.67%	$1.60M
Stempoint capital lp	160.42K	2.94%	$1.28M
Boothbay fund management	140.49K	2.58%	$1.12M
Birchview capital, lp	111.79K	2.05%	$893.17K
Blackrock funding, inc. /de	89.27K	1.64%	$713.28K
Mink brook asset management	66.81K	1.23%	$533.83K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rosalind advisors	221.62K	0.71%	$1.77M
Birchview capital, lp	111.79K	0.51%	$893.17K
Ikarian capital	508.56K	0.33%	$4.06M
Mink brook asset management	66.81K	0.30%	$533.83K
Exome asset management	60.86K	0.25%	$486.28K
Stempoint capital lp	160.42K	0.25%	$1.28M
Aigh capital management	200.00K	0.22%	$1.60M
Eversept partners, lp	294.99K	0.12%	$2.36M
Diadema partners lp	50.00K	0.07%	$399.50K
Persistent asset partners	13.44K	0.04%	$107.40K

Top Buyers

Holder	Shares	% Assets	Change
Ikarian capital	508.56K	0.33%	309.01K
Eversept partners, lp	294.99K	0.12%	294.99K
Rosalind advisors	221.62K	0.71%	221.62K
Aigh capital management	200.00K	0.22%	200.00K
Stempoint capital lp	160.42K	0.25%	160.42K

Top Sellers

Holder	Shares	% Assets	Change
Diadema partners lp	50.00K	0.07%	-210.94K
Persistent asset partners	13.44K	0.04%	-57.13K
Ameriprise financial	11.45K	-	-4.66K
Ubs group	3.49K	-	-2.11K
Morgan stanley	574.00	-	-177.00

New Positions

Holder	Shares	% Assets	Change	Value
Eversept partners, lp	294.99K	0.12%	294.99K	$2.36M
Rosalind advisors	221.62K	0.71%	221.62K	$1.77M
Aigh capital management	200.00K	0.22%	200.00K	$1.60M
Stempoint capital lp	160.42K	0.25%	160.42K	$1.28M
Birchview capital, lp	111.79K	0.51%	111.79K	$893.17K

Sold Out

Holder	Change
Citigroup	-3.00
Royal bank of canada	-73.00
Highmark wealth management	-100.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	18	-30.77%	650,772	-60.07%	11	1.32%	11	-26.67%	3	50.00%
Dec 31, 2025	14	-33.33%	459,539	-13.18%	8	8.68%	6	-14.29%	-	-100.00%
Sep 30, 2025	21	16.67%	529,307	0.16%	9	10.14%	7	16.67%	4	-33.33%
Jun 30, 2025	18	-5.26%	528,356	2.10%	9	10.55%	5	-54.55%	7	133.33%
Mar 31, 2025	19	11.76%	517,473	6.33%	9	11.64%	11	120.00%	3	-25.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	141.08K	2.64%	-
Vanguard Total Stock Mkt Idx Inv	142.77K	1.78%	-
Vanguard Institutional Extnd Mkt Idx Tr	57.90K	0.72%	-
Fidelity Extended Market Index	29.88K	0.40%	1.28K
Vifag 2002 SICAV	17.77K	0.33%	-
BlackRock Extended Equity Market K	12.86K	0.24%	-5.00
Extended Equity Market Fund E	14.75K	0.20%	-
Extended Equity Market Fund B	14.75K	0.20%	-
Blackrock Extended Mkt Fund CF	14.75K	0.18%	-
Extended Equity Market Fund K	12.56K	0.17%	-92.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 07, 2026	Higuchi John W.	-	Buy	$81.20K
Apr 06, 2026	Higuchi John W.	-	Buy	$252.15K
Apr 06, 2026	Patel Mahesh V.	Chief Executive Officer	Buy	$50.75K
Apr 02, 2026	Patel Mahesh V.	Chief Executive Officer	Buy	$50.50K
May 25, 2023	Patel Mahesh V.	CEO and President	Buy	$43.79K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	4	-
2026 Q1	-	-
2025 Q4	-	-
2025 Q2	-	-
2025 Q1	-	-

LPCN Ownership FAQ

Who Owns Lipocine?

Lipocine shareholders are primarily institutional investors at 11.94%, followed by 4.63% insiders and 83.43% retail investors. The average institutional ownership in Lipocine's industry, Biotech Stocks , is 35.75%, which Lipocine falls below.

Who owns the most shares of Lipocine?

Lipocine’s largest shareholders are Ikarian capital (508.56K shares, 9.33%), Eversept partners, lp (294.99K shares, 5.41%), and Vanguard group (221.87K shares, 4.10%). Together, they hold 18.85% of Lipocine’s total shares outstanding.

Does Blackrock own Lipocine?

BlackRock is not among the top 10 institutional shareholders of Lipocine.

Who is Lipocine’s biggest shareholder by percentage of total assets invested?

Rosalind advisors is Lipocine’s biggest shareholder by percentage of total assets invested, with 0.71% of its assets in 221.62K Lipocine shares, valued at 1.77M$.

Who is the top mutual fund holder of Lipocine shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Lipocine shares, with 2.64% of its total shares outstanding invested in 141.08K Lipocine shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools